Chemotherapy-Induced Anemia Market to Grow with a CAGR of 7.02% through 2030
Rising Incidence of Cancer and expanding geriatric population
are factors driving the global Chemotherapy-Induced Anemia market in the forecast
period 2026-2030.
According to TechSci Research report, “Chemotherapy-Induced
Anemia Market – Global Industry Size, Share, Trends, Competition Forecast
& Opportunities, 2030”, the Global Chemotherapy-Induced Anemia Market was
valued at USD 2.86 Billion in 2024 and is expected to reach USD 4.31 Billion by
2030 with a CAGR of 7.02% during the forecast period. The global
chemotherapy-induced anemia market has witnessed significant growth in recent
years, driven by various factors that have transformed the landscape of cancer
treatment. Chemotherapy-induced anemia is a common side effect of cancer
therapy, affecting a substantial portion of cancer patients. One of the
primary drivers behind the growth of the chemotherapy-induced anemia market is
the increasing incidence of cancer worldwide.
Advancements in cancer treatment over
the past few decades have significantly improved survival rates for cancer
patients. These advancements have primarily been driven by the development of
targeted therapies, immunotherapies, and precision medicine. Targeted therapies
work by specifically targeting cancer cells based on their genetic makeup,
minimizing harm to healthy cells. Immunotherapies, such as checkpoint
inhibitors, harness the body's immune system to recognize and attack cancer
cells more effectively. Precision medicine, which tailors treatments based on
an individual's genetic profile, has allowed for more personalized, effective
treatments that enhance outcomes. These groundbreaking therapies have offered
hope to many patients who once faced limited options. However, these innovative
treatments often come with side effects that can impact a patient's quality of
life. One of the most common and challenging side effects of cancer treatment
is anemia, particularly chemotherapy-induced anemia (CIA). This condition
occurs when cancer treatments, such as chemotherapy, interfere with the body's
ability to produce red blood cells, leading to fatigue, weakness, and a reduced
ability to cope with the side effects of cancer therapy.
As these cancer treatments continue to
advance, the demand for effective management of chemotherapy-induced anemia has
grown significantly. The need for anemia management solutions is now critical
to enhancing cancer patients' quality of life, improving their ability to
tolerate ongoing treatment, and boosting their overall survival rates. This
growing need for anemia treatments has led to a surge in demand for new and
innovative therapies aimed at mitigating the effects of chemotherapy-induced
anemia. In this context, various pharmaceutical companies have stepped up to
develop and introduce new treatments specifically designed to address anemia in
cancer patients. These solutions include erythropoiesis-stimulating agents
(ESAs), iron supplementation, and newer oral therapies like roxadustat, which
offer a less invasive approach to managing anemia.
In addition to advancements in cancer
therapies, demographic shifts are also contributing to the growing prevalence
of chemotherapy-induced anemia. The global population is rapidly aging, with a
significant increase in the number of elderly individuals. Aging is one of the
most significant risk factors for cancer, and older adults are more likely to
develop various types of cancer, including those that require aggressive
treatment like chemotherapy. As cancer becomes more prevalent in the aging
population, chemotherapy-induced anemia has become an even more pressing issue.
Older adults are often more vulnerable to the side effects of chemotherapy,
including anemia, due to age-related declines in overall health and organ
function. This demographic shift is contributing to the expansion of the
chemotherapy-induced anemia market, as it leads to a larger pool of potential
patients who need effective anemia management during their cancer treatment.
The increase in the elderly population in many countries, coupled with longer
life expectancies, means that there will likely be more individuals living with
cancer who will need interventions to address anemia.
There has been a
significant increase in awareness among healthcare providers and patients about
the impact of chemotherapy-induced anemia on the overall health and well-being
of cancer patients. Previously, anemia was often overlooked as a secondary
condition, but now there is a broader understanding of how it can diminish the
effectiveness of cancer treatments and negatively affect a patient's overall
prognosis. Patients who experience anemia may be more likely to require dose
reductions or interruptions in their chemotherapy regimen, which could lead to
suboptimal treatment outcomes. As awareness grows, healthcare professionals are
becoming more proactive in diagnosing and managing anemia in cancer patients,
thus creating a greater demand for treatments that address this issue. This
shift has resulted in improved detection and early intervention, helping
patients manage their symptoms more effectively and maintain a higher quality
of life throughout their treatment journey.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Chemotherapy-Induced Anemia Market”
The Global Chemotherapy-Induced Anemia Market is
segmented into disease type, treatment type, drug type, end user, region and company.
Based on end user, The Hospitals & Clinics segment is set to experience rapid growth during the forecast period, driven by the increasing demand for comprehensive cancer care services. These healthcare facilities are crucial in providing a wide range of treatments, including chemotherapy, radiation therapy, surgery, and supportive care. The management of chemotherapy-induced anemia (CIA) plays a vital role in their cancer treatment protocols. Hospitals and clinics are equipped with highly skilled oncologists, hematologists, and supportive care specialists, who work together to accurately diagnose and manage CIA. With access to the latest advancements in treatment, these institutions offer innovative therapies such as erythropoiesis-stimulating agents (ESAs), iron supplementation, and blood transfusions to effectively manage anemia and improve patient outcomes. The growing need for specialized care in cancer treatment, particularly in managing chemotherapy-induced side effects, is fueling the rapid expansion of this segment.
Based on region, Europe was the second dominant region in the global chemotherapy-induced anemia (CIA)
market, following North America in terms of market share. The growth of the CIA
market in Europe can be attributed to several key factors, including the high
incidence of cancer, advanced healthcare infrastructure, and a well-established
healthcare system that supports the timely diagnosis and management of
chemotherapy-induced anemia. Europe is home to a large and aging population,
both of which contribute to an increased incidence of cancer and, consequently,
chemotherapy-induced anemia. The region also has a high number of patients
undergoing chemotherapy treatments for various types of cancers, including
breast cancer, lung cancer, colorectal cancer, and prostate cancer, which are
among the most common cancers in Europe.
The
prevalence of chemotherapy-induced anemia in European cancer patients is
significantly high, leading to a growing demand for anemia management
solutions. Chemotherapy-induced anemia is a common side effect of cancer
treatment that results from chemotherapy drugs affecting the bone marrow’s
ability to produce red blood cells. This condition can result in debilitating
symptoms such as fatigue, weakness, and shortness of breath, which may reduce a
patient’s ability to tolerate chemotherapy treatments. Consequently, healthcare
providers in Europe are increasingly focusing on early diagnosis and treatment
of anemia in cancer patients to ensure better treatment outcomes and improve
patients’ quality of life. As a result, there is a strong emphasis on using medications
such as erythropoiesis-stimulating agents (ESAs) and intravenous iron
therapies, which are commonly prescribed to manage anemia in chemotherapy
patients.
Major companies operating in Global Chemotherapy-Induced
Anemia Market are:
- Dr.
Reddy's Laboratories Ltd.
- Pfizer
Inc.
- Panacea
Biotec Limited
- SBI
Pharmaceuticals Co., Ltd
- Sumitomo Dainippon Pharma Co., Ltd.
- PharmaEssentia
Corp.
- PhytoHealth
Corp
- UBI
Pharma Inc.
- Amgen Inc.
- Astellas Pharma Inc.
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The
global chemotherapy-induced anemia (CIA) market is poised for significant
growth in the coming years, driven by advancements in cancer treatments, an
aging population, and increased awareness of the impact of anemia on cancer
patients’ quality of life. The rising prevalence of cancer and the growing
number of chemotherapy patients are expected to drive demand for effective
anemia management solutions. Technological advancements in diagnostics and
personalized medicine will further fuel market growth by enabling more accurate
and tailored treatments. Additionally, ongoing research and the development of
innovative therapies, including novel erythropoiesis-stimulating agents and
iron supplements, will expand treatment options and improve patient outcomes.
As healthcare systems continue to focus on comprehensive cancer care, the CIA
market will experience sustained expansion globally.,” said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based management consulting
firm.
“Chemotherapy-Induced
Anemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
Segmented By Disease Type (Mild
Anemia, Moderate Anemia, Severe Anemia), By Treatment Type (RBC Transfusions, Erythropoiesis-stimulating
agents (ESAs), Iron Supplementation), By Drug Type (Epogen Injection, Procrit
Injection, Androxy Oral, Aranesp injection, Epoetin Alfa Injection, Others), By
End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition,
2020-2030F”, has evaluated
the future growth potential of Global Chemotherapy-Induced Anemia Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Chemotherapy-Induced Anemia Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com